阿达木单抗生物类似药BI 695501与修美乐参照药在中重度活动性类风湿关节炎患者中的疗效、安全性与免疫原性相似:III期随机VOLTAIRE-RA等效性研究结果
VOLTAIRE-RA研究将645例接受稳定甲氨蝶呤治疗的活动性类风湿关节炎患者随机分配至BI 695501或修美乐,第24周再次随机分为继续BI 695501、继续修美乐或由修美乐转换至BI 695501。第12周和第24周ACR20应答率的组间差异均在预设等效界值内,证实治疗等效;至第48周转换组与持续治疗组的疗效、安全性和免疫原性相似。
要点
- 第12周ACR20应答率BI 695501组67.0% vs 修美乐组61.1%(90%CI -0.9至12.7),第24周分别为69.0% vs 64.5%(95%CI -3.4至12.5),差异均在预设等效界值内。
- 第24周再随机后至第48周,转换组、持续BI 695501组和持续修美乐组的DAS28-ESR自基线变化及ACR20/50/70应答率相似。
- BI 695501与修美乐的抗药抗体、抗体滴度及中和抗体相似,组间安全性和耐受性特征相似。
核心结论
- BI 695501与修美乐在疗效、安全性和免疫原性方面相似;由修美乐转换至BI 695501对疗效、安全性和免疫原性无影响。
研究设计与样本
- III期随机、双盲、平行组等效性研究,纳入接受稳定甲氨蝶呤治疗的活动性类风湿关节炎患者,随机分配至BI 695501或修美乐。
- 第24周患者再次随机分为继续BI 695501、继续修美乐或由修美乐转换至BI 695501,疗效、安全性和免疫原性评估至第58周。
- 共645例患者被随机分配。
主要发现
- 第12周ACR20应答率BI 695501组(n=324)为67.0%,修美乐组(n=321)为61.1%,差异90%CI为-0.9至12.7。
- 第24周ACR20应答率BI 695501组为69.0%,修美乐组为64.5%,差异95%CI为-3.4至12.5。
- 第24周共593例患者再次随机分组;至第48周,转换组(n=147)、持续BI 695501组(n=298)和持续修美乐组(n=148)的DAS28-ESR自基线平均变化及ACR20/ACR50/ACR70应答率相似。
- 至第24周BI 695501与修美乐之间、至第48周各再随机分组之间的免疫原性(抗药抗体、抗体滴度及中和抗体)相似。
- 组间安全性和耐受性特征相似。
关键数值与推荐
- 共同主要终点为第12周和第24周达到ACR20应答标准的患者百分比。
- 预设等效界值:第12周90%CI为-12%至15%;第24周95%CI为-15%至15%。
- 第12周和第24周的组间差异均在预设等效界值内,证实治疗生物等效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira. METHODS: Patients with active rheumatoid arthritis on stable methotrexate were randomised to BI 695501 or Humira in a double-blind, parallel-group, equivalence study. At week 24, patients were rerandomised to continue BI 695501 or Humira, or switch from Humira to BI 695501. The coprimary endpoints were the percentage of patients achieving the American College of Rheumatology 20% response criteria (ACR20) at weeks 12 and 24. Further efficacy and safety endpoints and immunogenicity were assessed up to week 58. RESULTS: 645 patients were randomised. At week 12, 67.0% and 61.1% (90% CI -0.9 to 12.7) of patients receiving BI 695501 (n=324) and Humira (n=321), respectively, achieved ACR20; at week 24 the corresponding values were 69.0% and 64.5% (95% CI -3.4 to 12.5). These differences were within prespecified margins (week 12: 90% CI (-12% to 15%); week 24: 95% CI (-15% to 15%)), demonstrating therapeutic bioequivalence. 593 patients were rerandomised at week 24. Up to week 48, mean change from baseline in Disease Activity Score 28-erythrocyte sedimentation rate and ACR20/ACR50/ACR70 response rates were similar across the switched (n=147), continuous BI 695501 (n=298) and continuous Humira (n=148) groups. Similar immunogenicity (antidrug antibodies (ADAs), ADA titres and neutralising antibodies) was seen between BI 695501 and Humira (to week 24) and across rerandomised groups (to week 48). Safety and tolerability profiles were similar between groups. CONCLUSIONS: BI 695501 demonstrated similar efficacy, safety and immunogenicity to Humira; switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity. TRIAL REGISTRATION NUMBER: NCT02137226, Results.
引用
- Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018. PMID: 29514803. doi:10.1136/annrheumdis-2017-212245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。